Ultragenyx Pharmaceutical Inc (LTS:0LIF)
$ 51.134 -0.496 (-0.96%) Market Cap: 4.81 Bil Enterprise Value: 4.08 Bil PE Ratio: 0 PB Ratio: 10.88 GF Score: 72/100

Ultragenyx Pharmaceutical Inc Miss Con-GENE-iality - Updates in Gene Tx Panel at Wedbush PacGrow Healthcare Conference (Virtual) Transcript

Aug 11, 2021 / 04:00PM GMT
Release Date Price: $92.44
David Matthew Nierengarten
Wedbush Securities Inc., Research Division - MD & Head of Healthcare of Equity Research

Welcome to the 2021 Wedbush PacGrow Healthcare Conference. My name is David Nierengarten. I'm a senior analyst here at Wedbush Securities. And today, we are kicking off the Miss Con-GENE-iality gene therapy panel for -- of experts here in gene therapy. And with us today representing various different companies, we have Emil Kakkis, CEO of Ultragenyx; Geoff Mackay, CEO of AVROBIO; Bobby Gaspar, CEO of Orchard Therapeutics; and Philip Gregory, Chief Scientific Officer of bluebird bio.

And for those of you in the audience listening in, there should be a text box beneath a video screen that you can enter any questions you'd like to make this more interactive. And we will start off, though, with some questions and comments from yours truly and our panel members.

So first off, maybe just a quick introduction and description of your focus for each of our panel members, starting with Emil, and of course, on the focus for the gene therapy component of your business.

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot